Albumedix AS-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Albumedix AS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013133
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Albumedix A/S (Albumedix), a subsidiary of Novozymes A/S, is a developer of albumin-based products and technologies for advanced drug and vaccine formulation, extended drug half-life and improved drug delivery. Its product Recombumin is a recombinant human albumin used in the manufacture of human therapeutics, clinical-stage medical devices and cell therapies. The company also offers its drug delivery platform Veltis, which is used in marketed and late-stage clinical drug candidates. Albumedix’s provides products and services to pharmaceutical and biotech companies. The company has partnership with Teva Pharma, CSL Behring, GSK, Merck and Serendex among others. Albumedix is headquartered in Bagsvaerd, Denmark.

Albumedix AS – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Albumedix A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Albumedix A/S, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Albumedix A/S, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Albumedix A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Albumedix A/S, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Albumedix A/S, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Albumedix Acquires Albumin Variant Assets from Eleven Biotherapeutics 10
Partnerships 11
Albumedix Enters into Research Agreement with Oslo University Hospital and University of Oslo 11
Albumedix Enters into Research Agreement with NYU School of Medicine 12
Albumedix Enters into Agreement with ThioLogics 13
Equity Offering 14
Albumedix Spin Off from Novozymes 14
Albumedix A/S – Key Competitors 15
Albumedix A/S – Key Employees 16
Albumedix A/S – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Strategy And Business Planning 18
Jan 19, 2016: Novozymes separates its biopharma activities to form independent company 18
Corporate Communications 20
Oct 17, 2017: Albumedix Establishes Scientific Advisory Board 20
Jan 04, 2017: Albumedix appoints Chief Medical Officer 21
Product News 22
Jun 15, 2017: Albumedix to Host Webinar on Drug Formulation 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
Albumedix A/S, Pharmaceuticals & Healthcare, Key Facts 2
Albumedix A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Albumedix A/S, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Albumedix A/S, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Albumedix A/S, Deals By Therapy Area, 2011 to YTD 2017 8
Albumedix A/S, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Albumedix Acquires Albumin Variant Assets from Eleven Biotherapeutics 10
Albumedix Enters into Research Agreement with Oslo University Hospital and University of Oslo 11
Albumedix Enters into Research Agreement with NYU School of Medicine 12
Albumedix Enters into Agreement with ThioLogics 13
Albumedix Spin Off from Novozymes 14
Albumedix A/S, Key Competitors 15
Albumedix A/S, Key Employees 16
Albumedix A/S, Subsidiaries 17

★海外企業調査レポート[Albumedix AS-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cranswick plc:企業の戦略・SWOT・財務情報
    Cranswick plc - Strategy, SWOT and Corporate Finance Report Summary Cranswick plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Drone Aviation Holding Corp (DRNE):企業の財務・戦略的SWOT分析
    Summary Drone Aviation Holding Corp (Drone) operates as a technology company that develops, designs, markets and sells tethered drones, lighter-than-air advanced aerostats, and land-based intelligence, surveillance and reconnaissance solutions. The company’s products include drones, aerostat and mob …
  • Innovation Pharmaceuticals Inc (IPIX):製薬・医療:M&Aディール及び事業提携情報
    Summary Innovation Pharmaceuticals Inc (Innovation Pharmaceuticals), formerly Cellceutix Corp, is a biopharmaceutical company that discovers and advances medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications. The company provides pipeline products such as kevetr …
  • Spark Capital:企業のM&A・事業提携・投資動向
    Spark Capital - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Spark Capital Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Ecrins Therapeutics SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Ecrins Therapeutics SAS (Ecrins) is a biotechnology company that discovers and develops small molecule drug candidates against several oncology indications in humans and domestic animals. The company offers products such as native and labeled tubulin, tubulin polymerization kit, monoclonal a …
  • Indeck Energy Services Inc:企業の戦略的SWOT分析
    Indeck Energy Services Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Western Gas Partners LP (WES):企業の財務・戦略的SWOT分析
    Summary Western Gas Partners LP (Western Gas), a subsidiary of Anadarko Petroleum Corp is an oil and gas company that acquires, owns, develops and operates midstream energy assets. The company's services include processing, compressing, gathering, treating and transporting natural gas, natural gas l …
  • Anaconda Mining Inc:企業の戦略・SWOT・財務分析
    Anaconda Mining Inc - Strategy, SWOT and Corporate Finance Report Summary Anaconda Mining Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Faron Pharmaceuticals Oy (FARN):企業の財務・戦略的SWOT分析
    Summary Faron Pharmaceuticals Oy (Faron) is a clinical stage biopharmaceutical company that develops treatments for unmet medical needs. The company is developing pipeline products with a focus on vascular damage, acute organ traumas and cancer immunotherapy. It offers Clevegen, a humanized Clever-1 …
  • Constellation Brands, Inc.:戦略・SWOT・企業財務分析
    Constellation Brands, Inc. - Strategy, SWOT and Corporate Finance Report Summary Constellation Brands, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Aker ASA (AKER)-石油・ガス分野:企業M&A・提携分析
    Summary Aker ASA (Aker) is an industrial investment company, which operates through in two areas, Industrial Holdings and Financial Investments. It invests mainly in energy, environment, fisheries and marine biotech, and finance. Its Industrial Holdings include Aker Solutions ASA, Aker BP, Akastor A …
  • Monsanto Company:企業の戦略・SWOT・財務情報
    Monsanto Company - Strategy, SWOT and Corporate Finance Report Summary Monsanto Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • MPC Munchmeyer Petersen Capital AG (MPCK):企業の財務・戦略的SWOT分析
    Summary MPC Munchmeyer Petersen Capital AG (MPC), a subsidiary of MPC Munchmeyer Petersen & Co GmbH, is an asset and investment management firm. The firm business segments include infrastructure, real estate and shipping. Its real estate business concentrates on micro living or student housing. Its …
  • Xylem Inc (XYL):企業の財務・戦略的SWOT分析
    Xylem Inc (XYL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • BAM Nuttall Ltd:企業の戦略的SWOT分析
    BAM Nuttall Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Dufry AG (DUFN):企業の財務・戦略的SWOT分析
    Dufry AG (DUFN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • SolarWorld Industries GmbH:企業の戦略的SWOT分析
    SolarWorld Industries GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Nordic Nanovector ASA (NANO):企業の財務・戦略的SWOT分析
    Summary Nordic Nanovector ASA (Nordic Nanovector), formerly Nordic Nanovector AS is a developer and commercializer of antibody radionuclide conjugates for the treatment of hematological cancers. The company’s lead product candidate includes Betalutin, an antibody radionuclide conjugate developed for …
  • Miragen Therapeutics Inc (MGEN):医療機器:M&Aディール及び事業提携情報
    Summary Miragen Therapeutics, Inc. (Miragen) is a clinical stage biopharmaceutical company. It discovers and develops RNA-targeted therapeutics with a focus on microRNAs and their role in diseases. The company is developing its pipeline products for the treatment of Cutaneous T-Cell Lymphoma (CTCL), …
  • Diana S.A.S.:企業の戦略・SWOT・財務情報
    Diana S.A.S. - Strategy, SWOT and Corporate Finance Report Summary Diana S.A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆